2024
P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
de la Fuente R, Peleg A, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s323. DOI: 10.1016/j.jtho.2024.09.579.Peer-Reviewed Original Research
2023
EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer
Desland F, Fitzgerald B, Sheppard R, Van Hyfte G, Shimkus M, Rohs N, Veluswamy R, Rolfo C, Marron T, Smith C, Gomez J, Doroshow D. EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s644. DOI: 10.1016/j.jtho.2023.09.1225.Peer-Reviewed Original ResearchcfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations
Peleg A, Del Re M, Raphael A, Wang X, Berkovich A, Tsuriel S, Lichtman S, Elias E, Gomez J, Doroshow D, Smith C, Veluswamy R, Marron T, Rohs N, Mack P, Hirsch F, Rolfo C. cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations. The Journal Of Liquid Biopsy 2023, 1: 100047. DOI: 10.1016/j.jlb.2023.100047.Peer-Reviewed Original Research
2017
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.Peer-Reviewed Original ResearchConceptsBreast cancerAnti-HER2 monoclonal antibody trastuzumabManagement of HER2Single-agent trastuzumabTumor-directed cytotoxicityAcceptable toxicity profileFirst-line treatmentPhase III trialsMonoclonal antibody trastuzumabAdjuvant managementIII trialsOverall survivalAdvanced HER2Cardiac toxicityTrastuzumab emtansineAgent trastuzumabToxicity profileAntibody trastuzumabSystemic toxicityHER2CancerTrastuzumabStable linkerOngoing studiesToxicity